Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDX-1140 + gemcitabine + nab-paclitaxel
- Development stage
- Preclinical
- Lead developer
- Celldex Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CDX-1140 + gemcitabine + nab-paclitaxel is an experimental combination regimen comprising a fully human CD40 agonist monoclonal antibody (CDX-1140), a nucleoside analog antimetabolite (gemcitabine), and a nanoparticle albumin-bound formulation of paclitaxel (nab-paclitaxel). CDX-1140 is designed to activate antigen-presenting cells such as dendritic cells and B cells by agonizing CD40, thereby enhancing antitumor immune responses independent of Fc receptor interactions. Gemcitabine inhibits DNA synthesis in rapidly dividing tumor cells, while nab-paclitaxel stabilizes microtubules, preventing cell division. This combination is being investigated for its potential synergistic immunotherapeutic and cytotoxic effects against advanced cancers. Early clinical studies are primarily in solid tumors, including pancreatic and biliary tract cancer, particularly for patients who have progressed on standard first-line therapies[1].
- Brand names
- AbraxaneGemzar
- Other names
- CDX-1140 + gemcitabine + nab-paclitaxel
02
Targets
CD40 (Cluster of differentiation 40 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CDX-1140 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDX-1140 + gemcitabine + nab-paclitaxel.